December 2016
-
Job Title: Scientist II, Pharmaceutical Development Location: Florida, Lupin USA Inc. Function: R&D Reports to: Manager, Pharmaceutical Development Summary Conducts routine and non-routine laboratory activities following with minimal supervision and contributes to innovative and investigative… Read more . . .
-
Job Title: Senior Scientist, Formulations Location: Florida, Lupin USA Inc. Function: R&D Reports to: Director of Pharmaceutical Development Summary Independently conducts standard and advanced laboratory activities including evaluation and selection of raw materials, formulation development… Read more . . .
-
Job Title: Principal Scientist, Formulations Location: Florida, Lupin USA Inc. Function: R&D Reports to: Director, Pharmaceutical Development Summary Supervise standard and advanced laboratory activities including evaluation and selection of raw materials and formulation development of… Read more . . .
-
Job Title: Fellow, Research Location: Florida, Lupin USA Inc. Function: R&D Reports to: Senior Director, Inhalation R&D Summary Provides technical leadership in Research activities within Lupin Respiratory R&D Florida, functions as analytical and product characterization… Read more . . .
-
Job Title: Scientist I, Pharmaceutical Development Location: Florida, Lupin USA Inc. Function: R&D Reports to: Manager, Pharmaceutical Development Summary Conducts routine and non-routine laboratory activities following with minimal supervision. Assures that Quality standards are met.… Read more . . .
-
Submit podium presentation proposals by February 28, 2014 at http://www.rddonline.com/rdd/speaker_reg.php?id=10 Workshop proposals should be submitted to http://www.rddonline.com/rdd/workshop_reg.php?id=10&sid=6 by February 14. Read more . . .
-
Rexam has announced the decision to sell all three divisions of its Healthcare business: Pharmaceutical Devices, Prescription Retail Packaging and Closures & Containers. Montagu Private Equity has made an offer of $805 million for the… Read more . . .
-
Sanofi US consumer healthcare division Chattem has announced that Nasacort Allergy 24HR Nasal Spray is now available over the counter in the United States. The FDA approved the triamcinolone acetonide nasal spray as an OTC… Read more . . .
-
Bill Doub is Lead Chemist, R&D in the FDA’s Division of Pharmaceutical Analysis, which is part of the Office of Pharmaceutical Science in the Center for Drug Evaluation and Research (CDER). . . . Read… Read more . . .
-
Civitas Therapeutics has announced that former Sunovion CEO Mark Iwicki will succeed Glenn Batchelder as President and Chief Executive Officer. Iwicki was most recently CEO of Blend Therapeutics. According to Civitas, which is developing inhaled… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland